ATNAHS PHARMA UK LIMITED
Get an alert when ATNAHS PHARMA UK LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£14m
EUR 15,853,000
-33.5% lowest in 3 filed years
Net assets
-£322m
EUR -370,190,000
-16.6% lowest in 3 filed years
Employees
294
-13% lowest in 3 filed years
Profit before tax
-£67m
EUR -77,367,000
+80.7% vs 2025
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
4 officer resignations in last 12 months
Multiple officers have left the board recently — see the People section for who.
-
Negative shareholders' funds
Net assets
3-year trend · vs Health Care median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2026-03-31
| Metric | Trend | 2024-03-31 | 2025-03-31 | 2026-03-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £316,918,669 | £227,736,653 | £215,411,816 | -5.4% | |
| Operating profit | £73,103,566 | -£328,691,620 | -£35,262,381 | +89.3% | |
| Profit before tax | £47,282,990 | -£348,796,056 | -£67,217,202 | +80.7% | |
| Net profit | £52,510,904 | — | — | — | |
| Cash | £35,746,173 | £20,711,839 | £13,773,241 | -33.5% | |
| Total assets less current liabilities | £800,069,272 | £350,973,348 | £320,871,416 | -8.6% | |
| Net assets | £53,301,120 | -£275,917,788 | -£321,624,674 | -16.6% | |
| Equity | £53,301,120 | -£275,917,788 | -£321,624,674 | -16.6% | |
| Average employees | 315 | 338 | 294 | -13% | |
| Wages | £19,787,907 | £18,359,094 | £17,939,183 | -2.3% | |
| Directors' remuneration | £1,709,570 | £1,325,925 | £2,602,085 | +96.2% | |
| Directors' pension contributions | £54,734 | £60,991 | £59,079 | -3.1% | |
| Highest paid director | £768,836 | £446,988 | £1,145,960 | +156.4% |
Figures converted to GBP from EUR at 0.869 per EUR (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|
| Operating margin | 23.1% | -144.3% | -16.4% | |
| Net margin | 16.6% | — | — | |
| Return on capital employed | 9.1% | -93.7% | -11.0% | |
| Gearing (liabilities / total assets) | 94.3% | 152.3% | 177.2% | |
| Current ratio | 1.87x | 1.15x | 1.76x | |
| Interest cover | 2.65x | -15.87x | -1.10x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- ATNAHS PHARMA UK LIMITED 2014-04-23 → present
- ATNAHS UK HOLDINGS LIMITED 2013-11-25 → 2014-04-23
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Consolidated group
- Auditor
- S&W Audit
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors have assessed the ability of the Atnahs group ('the group'), to continue as a going concern for a period of at least twelve months from the date of approval of these financial statements.”
Group structure
- ATNAHS PHARMA UK LIMITED · parent
- Marlborough Pharmaceuticals Limited 100%
- Atnahs Pharma US Limited 100%
- Atnahs Pharma Australia Pty Limited 100%
- Pharmanovia A/S 100%
- Atnahs Pharma Denmark ApS 100%
- Pharmanovia India Private Limited 100%
- Pharmanovia Italy S.R.L. 100%
- Atnahs Pharma Switzerland AG 100%
- Pharmanovia APAC PTE Ltd 100%
- Pharmanovia Korea Limited 100%
- Pharmanovia Belgium B.V 100%
- Pharmanovia España, S.L.U 100%
- Pharmanovia GmbH 100%
- Atnahs Pharma France 100%
- Pharmanovia Benelux B.V 100%
- Atnahs Pharma Netherlands B.V 100%
Significant events
- “In December 2025, further information can be found in note 29. The sale aligns with the strategic priorities and allows for further focus of resources where the business can grow and complete most effectively, whilst also having utilised the proceeds to de-leverage the balance sheet.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 14 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| PARSONS, John-Albert | Secretary | 2026-08-27 | — | — |
| EDER, Stephan, Dr | Director | 2025-10-10 | Jul 1975 | Austrian |
| OMAR, Shiraz Shamshudin | Director | 2026-04-15 | May 1969 | British |
| OWEN, James Mark | Director | 2025-10-10 | Mar 1982 | British |
Show 14 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| VISTRA COMPANY SECRETARIES LIMITED | Corporate Secretary | 2016-05-23 | 2023-09-29 |
| BURT, James Charles | Director | 2021-12-07 | 2025-04-01 |
| COTTERILL, Mark John | Director | 2013-11-25 | 2019-08-07 |
| FLOREZ, Felipe | Director | 2021-06-01 | 2023-05-22 |
| HAY, Alastair Thomas Badgett | Director | 2019-08-07 | 2021-12-07 |
| JAVEED, Zubair | Director | 2025-04-01 | 2025-10-10 |
| PATEL, Amit Vijaykumar | Director | 2019-08-07 | 2026-03-19 |
| PATEL, Amit Vijaykumar | Director | 2013-11-25 | 2019-08-07 |
| PATEL, Bhikhu Chhotabhai | Director | 2013-11-25 | 2019-08-07 |
| PATEL, Dipen Vijaykumar | Director | 2013-11-25 | 2019-08-07 |
| PATEL, Rishi Bhikhu | Director | 2019-08-07 | 2022-06-30 |
| PATEL, Santsagar | Director | 2024-06-17 | 2026-01-20 |
| PATEL, Vijay Kumar Chhotabhai | Director | 2013-11-25 | 2019-08-07 |
| WILLIAMS, Neeshe | Director | 2019-08-07 | 2026-07-27 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Pharmanovia Bidco Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-11-04 | Active |
| Mr Vijay Kumar Chhotabhai Patel | Individual | Shares 50–75%, Voting 25–50% | 2016-04-06 | Ceased 2019-11-04 |
Filing timeline
Last 20 of 118 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-09-21 | AA | accounts | Accounts with accounts type group | |
| 2026-09-08 | AP03 | officers | Appoint person secretary company with name date | |
| 2026-08-12 | TM01 | officers | Termination director company with name termination date | |
| 2026-04-30 | AP01 | officers | Appoint person director company with name date | |
| 2026-03-20 | TM01 | officers | Termination director company with name termination date | |
| 2026-03-09 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-02-13 | TM01 | officers | Termination director company with name termination date | |
| 2026-01-29 | CH01 | officers | Change person director company with change date | |
| 2026-01-05 | AA | accounts | Accounts with accounts type group | |
| 2025-11-05 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-10-28 | AP01 | officers | Appoint person director company with name date | |
| 2025-10-27 | AP01 | officers | Appoint person director company with name date | |
| 2025-10-16 | TM01 | officers | Termination director company with name termination date | |
| 2025-06-16 | CH01 | officers | Change person director company with change date | |
| 2025-06-16 | CH01 | officers | Change person director company with change date | |
| 2025-05-01 | TM01 | officers | Termination director company with name termination date | |
| 2025-05-01 | AP01 | officers | Appoint person director company with name date | |
| 2024-11-29 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-11-14 | AA | accounts | Accounts with accounts type group | |
| 2024-07-05 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 13
- Capital events
- 0
- Officers appointed
- 4
- Officers resigned
- 4
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.